systemic exposure. 461 l° See the guidance for industry E I 4 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. 2° See the revised draft guidance for industry Suicidal Ideation and Behavior Prospective Assessment of Occurrence in Clinical Trials. When final,